CN112842985A - 一种保湿修护组合物 - Google Patents
一种保湿修护组合物 Download PDFInfo
- Publication number
- CN112842985A CN112842985A CN202110170020.3A CN202110170020A CN112842985A CN 112842985 A CN112842985 A CN 112842985A CN 202110170020 A CN202110170020 A CN 202110170020A CN 112842985 A CN112842985 A CN 112842985A
- Authority
- CN
- China
- Prior art keywords
- moisturizing
- parts
- composition
- skin
- repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 32
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000008439 repair process Effects 0.000 claims abstract description 25
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 20
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 20
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 20
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 13
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 13
- 229960000458 allantoin Drugs 0.000 claims abstract description 13
- 229940101267 panthenol Drugs 0.000 claims abstract description 13
- 239000011619 pantothenol Substances 0.000 claims abstract description 13
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 13
- 229930182478 glucoside Natural products 0.000 claims abstract description 11
- -1 glycerol glucoside Chemical class 0.000 claims abstract description 11
- SJSBCEWQGMXBCJ-UHFFFAOYSA-N CCOC(CCCCCOC(CCC(O)=O)=O)OCC Chemical compound CCOC(CCCCCOC(CCC(O)=O)=O)OCC SJSBCEWQGMXBCJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 9
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims abstract 2
- 229940044176 ceramide 3 Drugs 0.000 claims abstract 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 12
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 12
- 229940106189 ceramide Drugs 0.000 claims description 12
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 12
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 6
- 229920001503 Glucan Polymers 0.000 claims description 5
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 4
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229940094944 saccharide isomerate Drugs 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 53
- 235000007319 Avena orientalis Nutrition 0.000 description 10
- 241000209763 Avena sativa Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SWQUTKGVXGTROS-UHFFFAOYSA-N bis(2-ethoxyethyl) butanedioate Chemical compound CCOCCOC(=O)CCC(=O)OCCOCC SWQUTKGVXGTROS-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229940119676 diethoxyethyl succinate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940104256 sodium taurate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种保湿修护组合物,属于日用化妆品领域。本发明保湿修护组合物包括以下组分:神经酰胺3、尿囊素、燕麦仁提取物、透明质酸钠组合物、泛醇、糖类同分异构体、甘油葡糖苷和琥珀酸二乙氧基己酯。通过修护肌肤表皮层、补充肌肤天然保湿因子和形成透气保湿膜,三方面结合保湿修复,修复肌肤屏障,增强肌肤自身锁水保湿能力,治标更治本,让肌肤长效维持水润状态。
Description
技术领域
本发明涉及一种保湿修护组合物,属于日用化妆品领域。
背景技术
目前市面上的保湿产品比比皆是,但是市面上的保湿产品多数为保湿效果一般的即时补水产品,长效保湿效果不佳。然而随着城市环境与生活方式的变化,敏感肌消费者日渐增多,而敏感肌患者的皮肤问题主要是由于皮肤屏障受损引起的,通过简单短暂的补水保湿不能从根本上解决肌肤缺水干燥的问题,导致敏感肌消费者对保湿产品的需求得不到充分的满足。
发明内容
本发明的目的在于克服上述现有技术的不足之处而提供一种保湿效果优异且同时具有修护效果的保湿修护组合物。
为实现上述目的,本发明采取的技术方案为:一种保湿修护组合物,其包括以下组分:神经酰胺、尿囊素、燕麦仁提取物、透明质酸钠组合物、泛醇、糖类同分异构体、甘油葡萄糖苷和琥珀酸二乙氧基己酯。
神经酰胺是可以使角质蛋白有规律的再生,促进细胞新陈代谢,并能传导细胞信息的一种无色透明,呈液态的水溶性脂质。角质层的皮脂包括50%的神经酰胺、30%的游离脂肪酸、15%的胆固醇和5%的胆固醇酯,神经酰胺在整个角质层中含量最多,充当的角色最重要。神经酰胺具有很强缔合水分子能力,它通过在角质层中形成网状结构维持皮肤水分,具有维持皮肤屏障、保湿、抗衰老、美白和疾病治疗等作用。尿囊素是尿酸的衍生物,尿酸作为一种抗氧化剂,和自由基作用后产生尿囊素,尿囊素能够直接作用与皮肤的角蛋白,增加和促进角质层的水合能力,减少水分的损失,可以滋润皮肤使皮肤变得光滑、湿润和柔韧,可以缓解和治疗皮肤干燥症;同时尿囊素还具有促进细胞生长、加快伤口愈合、软化角质蛋白的生理功能。燕麦(AVENA SATIVA)仁提取物的主要作用是修复肌肤屏障,舒缓敏感,增强皮肤耐受力,降低敏感度。神经酰胺、尿囊素和燕麦仁提取物复配能够起到修护肌肤真皮层的作用。
透明质酸钠主要的功效是保湿,属于目前保湿性最强的一种保湿因子,其次透明质酸钠,可以修复皮肤损伤,促进表皮细胞的增殖和分化,清除氧自由基,延缓皮肤衰老,还有除皱的作用。泛醇能够刺激表皮细胞的生长,容易吸收、渗透和渗透皮肤表面的角质层。泛醇还具有抗炎作用,能延缓炎症反应的进程;泛醇具有强大的强化皮肤屏障的作用,特别是与烟酰胺结合时,使皮肤能更好地抵御外界因素的刺激。糖类同分异构体(SACCHARIDEISOMERATE)是2015版国家公布的化妆品原料之一,其类似于人体内的碳水化合物的复合体,亲肤性能佳,其通过与角质层细胞中角蛋白上的赖氨酸的自由氨基酸基团结合,协助角质层的角蛋白结合水分,因不能被轻易洗掉,以达到持久的保湿效果。甘油葡糖苷可提高表皮层中水通道蛋白的含量,增强皮肤的屏障功能,减少经皮水分的蒸发,对皮肤有保湿作用。透明质酸钠、泛醇、糖类同分异构体进而甘油葡糖苷复配可以补充肌肤天然保湿因子,达到成膜保湿和深度补水双重保湿效果。
琥珀酸二乙氧基己酯是由琥珀酸和乙氧基乙醇反应生成的二酯,呈无色透明状态。琥珀酸二乙氧基己酯和上述化合物复配可以形成透气保湿膜,锁住肌肤水分,增加肌肤保湿时长。
作为本发明保湿修护组合物的优选实施方式,所述保湿修护组合物包括以下重量份的组分:0.2-1份神经酰胺、0.08-0.12份尿囊素、0.1-0.5份燕麦仁提取物、0.06-0.25透明质酸钠组合物、0.1-0.5份泛醇、0.01-0.8份糖类同分异构体、0.5-1.5份甘油葡糖苷和0.5-4份琥珀酸二乙氧基己酯。
组分的配比影响本发明保湿修护组合物的保湿修护效果,研究表明,当上述组分在上述范围时,本发明保湿修护组合物的保湿修护效果更好。
作为本发明保湿修护组合物的优选实施方式,所述保湿修护组合物包括以下重量份的组分:1份神经酰胺、0.1份尿囊素、0.5份燕麦仁提取物、0.15透明质酸钠组合物、0.5份泛醇、0.5份糖类同分异构体、1份甘油葡糖苷和3份琥珀酸二乙氧基己酯。
当上述组分在上述范围时,本发明保湿修护组合物的保湿修护效果最佳。
作为本发明保湿修护组合物的优选实施方式,所述透明质酸钠组合物由透明质酸钠和水解透明质酸钠组成。
不同分子量的透明质酸钠起到的作用不同,大分子的透明质酸钠,主要是起到交联支撑填充的作用,小分子透明质酸钠主要作用是补水、抗皱、抗衰老,改善皮肤的肤质、提高皮肤的光泽度。
作为本发明保湿修护组合物的优选实施方式,还包括以下重量份的组分:0.5份己二醇、0.1-1.5份水解蚕丝、0.5-3份葡聚糖和0.5-3份烟酰胺。
己二醇的主要作用是保湿,能够改善产品的肤感、温和无刺激,合理用量下,还可起到防腐作用。水解蚕丝含有极高的胶原蛋白和弹力纤维,氨基酸、核糖、核酸等营养成份,它与人体胶原蛋白完全相同,能被肌肤吸收,促进细胞在生,紧致细胞间隙距离,提升肌肤柔韧度和紧致度,使肌肤清爽、白细、富有弹性。
葡聚糖能够提高皮肤的免疫力,帮助受损皮肤的组织恢复产生细胞素,尤其对于激素依赖性皮炎或者皮肤屏障功能受到破坏的皮肤有一定的作用;葡聚糖可以增加表皮生长英子促进皮肤中胶原蛋白和弹性蛋白的增加,同时该葡聚糖还具有防晒作用,并且能够减少局部炎症和疼痛;还具有一定的抗过敏作用,可以用来帮助敏感皮肤的修复。
烟酰胺是辅酶I和辅酶II的组成部分,在生物氧化呼吸链中起着递氢的作用,可促进生物氧化过程和组织新陈代谢,对维持正常组织的完整性具有重要作用,可以很好的修复角质层,强化皮肤自身防御能力。
作为本发明保湿修护组合物的优选实施方式,还包括以下重量份的组分:0.05-0.15份黄原胶和0.3-0.5份丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物。
黄原胶又称黄胶、汉生胶,是一种由黄单胞杆菌发酵产生的细胞外酸性杂多糖。是由D-葡萄糖、D-甘露糖和D-葡萄糖醛酸按2:2:1组成的多糖类高分子化合物,相对分子质量在100万以上。黄原胶的二级结构是侧链绕主链骨架反向缠绕,通过氢键维系形成棒状双螺旋结构。黄原胶溶胶分子能形成超结合带状的螺旋共聚体,构成类似胶的网状结构,所以能够支持固体颗粒、液滴和气泡的形态,显示出很强的乳化稳定作用和高悬浮能力。丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物的CAS号为111286-86-3,它是一种增稠剂,能够起到成膜、分散、乳化、增稠的作用。
作为本发明保湿修护组合物的优选实施方式,还包括0.4-0.5重量份对羟基苯乙酮。
对羟基苯乙酮,是一款温和、无添加、无刺激防腐剂,同时具有抗氧化、镇静舒缓的功能。
作为本发明保湿修护组合物的优选实施方式,还包括以下重量份的组分:6-15份甘油。
甘油涂在皮肤上可以使皮肤的表面形成一层无形的保护膜,使皮肤与外界的空气保持隔离,为皮肤抵挡外界环境所带来的侵袭,从而起到保护皮肤的作用。
此外,本发明还提供了一种包含保湿修护组合物的膏霜剂、水剂或乳剂。
与现有技术相比,本发明的有益效果为:
(1)修护肌肤表皮层:通过补充皮肤固有的脂质成分神经酰胺,修护表皮层,加强表皮屏障,以降低外界刺激对肌肤的影响,同时锁住肌肤水分,减少水分蒸发;同时和尿囊素,葡聚糖与燕麦(AVENA SATIVA)仁提取物复配,舒缓呵护,帮助肌肤自我修复,同时保持皮肤水分;
(2)补充肌肤天然保湿因子:通过复配不同分子量的天然保湿因子透明质酸钠,达到成膜保湿和深度补水双重滋润效果,辅以泛醇的深度修护保湿和糖类同分异构体的长效保湿以及甘油葡糖苷的多维度保湿,为肌肤提供多方位,高水平的保湿因子;
(3)形成透气保湿膜:添加特殊油脂琥珀酸二乙氧基己酯,形成透气保湿膜,锁住肌肤水分,增加肌肤保湿时长。
三方面结合保湿修复,修复肌肤屏障,增强肌肤自身锁水保湿能力,治标更治本,让肌肤长效维持水润状态。
附图说明
图1为对照组、实施例1~3和对比例1~3所述保湿修护组合物的补水保湿效果图;
图2为实施例2、3所述保湿修护组合物的感官评价图;
图3为实施例2所述保湿修护组合物的修复效果图。
具体实施方式
本发明实施例和对比例中的原料均购自市面。
为更好的说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。
实施例1~3和对比例1~3保湿修护组合物的组成成分如表1所示。
实施例1~3和对比例1~3保湿修护组合物的制备方法包括以下步骤:
1.将甘油,黄原胶,丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物分散均匀,加入水,尿囊素,对羟基苯乙酮,然后加热至85℃,溶解分散完全,保温10分钟;
2.步骤1中的产品降温至60℃后,加入透明质酸和水解透明质酸钠,溶解分散完全;
3.继续降温至40℃后,加入泛醇,烟酰胺,葡聚糖,水解蚕丝,己二醇,神经酰胺,糖类同分异构体,甘油葡糖苷,燕麦(AVENA SATIVA)仁提取物,琥珀酸二乙氧基乙酯,柠檬酸,柠檬酸钠,搅拌溶解均匀;
4.送样检测合格后过滤出料,即得所述保湿修护组合物。
表1
注:表1中的组成成分的含量单位均为重量份。
实施例4
测试实施例1~3所述保湿修护组合物的稳定性,结果如表2所示。
表2保湿修护组合物的稳定性测试结果
注:“√”指无异常,“—”指未检出。“通过”结果对应-15℃和+48℃指恢复至室温,料体外观与室温放置样品无差异,PH,粘度,透明度等理化指标无变化;对应细菌霉菌指微生物测试未检测出相应菌落。
由表1可得,实施例1~3所述保湿修护组合物皆通过稳定性测试,属于稳定性配方,可工业化生产。
实施例5
测试实施例1~3和对比例1~3所述保湿修护组合物的补水保湿效果。
测试方法:肌肤手臂内侧涂抹保湿修护组合物,通过肌肤水分测试仪测试肌肤手臂内侧的水分含量,每组数据皆测量三次取平均值。测试结果如表3和表4所示。其中对照组为纯水。
表3保湿修护组合物的补水保湿测试结果
由表3可以看出,实施例1~3所述保湿修护组合物均具有保湿补水效果,其中实施例2所述保湿修护组合物即时补水与长效保湿的效果最佳。
实施例6
测试实施例2和实施例3的使用感。
测试方法:保湿修护组合物经由感官测试中心选取15名感官体验者测试,分值由1-5表示满意程度,1为最低,5为最高。测试结果如表5和表6所示。
表5实施例2所述保湿修护组合物感官测试数据
表6实施例3所述保湿修护组合物感官测试数据
图2为实施例2和实施例3所述保湿修护组合物的感官评价图。由图2可知实施例2的吸收快慢程度比实施例3低,其他效果均比实施例3高,由此可知实施例2的保湿效果最佳。
实施例7
选用实施例2所述保湿修护组合物进行皮肤屏障修护测试,结果通过Visia-CR仪器测试成像体现,以红色表示肌肤敏感程度与区域,如皮肤红区减小,红色程度变浅,视为屏障功能改善。结果如图3所示,使用实施例2所述保湿修护组合物28天后,皮肤红色区域与红色深浅均有一定程度的减小,表明实施例2所述保湿修护组合物具有一定修护肌肤屏障的功效。其中由于测试者为敏感痤疮肌肤,成像图中深色点状为测试者面部的痤疮或黑痣,非敏感测试指标,主要考量指标为整脸红色区域大小和深浅程度。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (9)
1.一种保湿修护组合物,其特征在于,包括以下组分:神经酰胺3、尿囊素、燕麦仁提取物、透明质酸钠组合物、泛醇、糖类同分异构体、甘油葡糖苷和琥珀酸二乙氧基己酯。
2.如权利要求1所述保湿修护组合物,其特征在于,所述保湿修护组合物包括以下重量份的组分:0.2-1份神经酰胺、0.08-0.12份尿囊素、0.1-0.5份燕麦仁提取物、0.06-0.25透明质酸钠组合物、0.1-0.5份泛醇、0.01-0.8份糖类同分异构体、0.5-1.5份甘油葡糖苷和0.5-3份琥珀酸二乙氧基己酯。
3.如权利要求2所述保湿修护组合物,其特征在于,所述保湿修护组合物包括以下重量份的组分:0.2份神经酰胺、0.1份尿囊素、0.5份燕麦仁提取物、0.15透明质酸钠组合物、0.5份泛醇、0.5份糖类同分异构体、1份甘油葡糖苷和3份琥珀酸二乙氧基己酯。
4.如权利要求1~3任一项所述保湿修护组合物,其特征在于,所述透明质酸钠组合物由透明质酸钠和水解透明质酸钠组成。
5.如权利要求2所述保湿修护组合物,其特征在于,还包括以下重量份的组分:0.5份己二醇、0.1-1.5份水解蚕丝、0.5-3份葡聚糖和0.5-3份烟酰胺。
6.如权利要求6所述保湿修护组合物,其特征在于,还包括以下重量份的组分:0.05-0.15份黄原胶和0.3-0.5份丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物。
7.如权利要求7所述保湿修护组合物,其特征在于,还包括0.4-0.5重量份对羟基苯乙酮。
8.如权利要求8所述保湿修护组合物,其特征在于,还包括以下重量份的组分:6-15份甘油和77-79份水。
9.一种包含权利要求1~9中任一项所述保湿修护组合物的膏霜剂、水剂或乳剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110170020.3A CN112842985A (zh) | 2021-02-08 | 2021-02-08 | 一种保湿修护组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110170020.3A CN112842985A (zh) | 2021-02-08 | 2021-02-08 | 一种保湿修护组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112842985A true CN112842985A (zh) | 2021-05-28 |
Family
ID=75989075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110170020.3A Pending CN112842985A (zh) | 2021-02-08 | 2021-02-08 | 一种保湿修护组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112842985A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114480531A (zh) * | 2021-12-17 | 2022-05-13 | 广州栋方生物科技股份有限公司 | 一种甘油葡糖苷的制备方法、产物及其应用 |
CN114569479A (zh) * | 2021-12-01 | 2022-06-03 | 凡可化妆品研究开发(广州)有限公司 | 一种含泛醇组合物以及护肤品 |
CN115444772A (zh) * | 2022-10-26 | 2022-12-09 | 广州艾卓生物科技股份有限公司 | 一种保湿美白组合物及其在射频美容和医美护肤中的应用 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784092A (zh) * | 2015-04-02 | 2015-07-22 | 沈阳伊霏霖生物科技有限公司 | 一种皮肤即时修复营养液 |
CN108158876A (zh) * | 2017-12-25 | 2018-06-15 | 陕西佰傲再生医学有限公司 | 一种皮肤保湿修护组合物及其制备方法 |
CN108721153A (zh) * | 2018-07-28 | 2018-11-02 | 上海煓梅生物科技有限公司 | 一种含有海星枝管藻提取物的保湿组合及其制备方法 |
CN109010205A (zh) * | 2018-08-29 | 2018-12-18 | 广州四环康源化妆品有限公司 | 一种敏感肌修复组合物及其制备方法 |
CN109381367A (zh) * | 2018-12-17 | 2019-02-26 | 贺鹏 | 一种婴儿专用的蛋白质乳霜 |
CN109481327A (zh) * | 2018-12-04 | 2019-03-19 | 珠海依赛思生物科技有限公司 | 一种多效修护肽精华组合物及其制备方法 |
CN109662928A (zh) * | 2019-02-14 | 2019-04-23 | 成都市葆姿健康管理有限公司 | 一种具有防晒修复功效的护肤组合物及其应用和制备方法 |
CN110302081A (zh) * | 2019-07-29 | 2019-10-08 | 广州药妆日用化工有限公司 | 一种双重玻尿酸原液及其制备方法 |
CN111529444A (zh) * | 2020-05-25 | 2020-08-14 | 湖北省麦诗特生物科技有限公司 | 一种具有皮肤屏障修复功能的组合物及其制备方法与应用 |
CN111658566A (zh) * | 2020-06-30 | 2020-09-15 | 广州市瑞芬化妆品有限公司 | 一种深层补水修复面部滋养霜及其制备方法 |
CN112263497A (zh) * | 2020-10-23 | 2021-01-26 | 上海新高姿化妆品有限公司 | 一种具有舒缓修复抗敏功效的护肤品组合物 |
-
2021
- 2021-02-08 CN CN202110170020.3A patent/CN112842985A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784092A (zh) * | 2015-04-02 | 2015-07-22 | 沈阳伊霏霖生物科技有限公司 | 一种皮肤即时修复营养液 |
CN108158876A (zh) * | 2017-12-25 | 2018-06-15 | 陕西佰傲再生医学有限公司 | 一种皮肤保湿修护组合物及其制备方法 |
CN108721153A (zh) * | 2018-07-28 | 2018-11-02 | 上海煓梅生物科技有限公司 | 一种含有海星枝管藻提取物的保湿组合及其制备方法 |
CN109010205A (zh) * | 2018-08-29 | 2018-12-18 | 广州四环康源化妆品有限公司 | 一种敏感肌修复组合物及其制备方法 |
CN109481327A (zh) * | 2018-12-04 | 2019-03-19 | 珠海依赛思生物科技有限公司 | 一种多效修护肽精华组合物及其制备方法 |
CN109381367A (zh) * | 2018-12-17 | 2019-02-26 | 贺鹏 | 一种婴儿专用的蛋白质乳霜 |
CN109662928A (zh) * | 2019-02-14 | 2019-04-23 | 成都市葆姿健康管理有限公司 | 一种具有防晒修复功效的护肤组合物及其应用和制备方法 |
CN110302081A (zh) * | 2019-07-29 | 2019-10-08 | 广州药妆日用化工有限公司 | 一种双重玻尿酸原液及其制备方法 |
CN111529444A (zh) * | 2020-05-25 | 2020-08-14 | 湖北省麦诗特生物科技有限公司 | 一种具有皮肤屏障修复功能的组合物及其制备方法与应用 |
CN111658566A (zh) * | 2020-06-30 | 2020-09-15 | 广州市瑞芬化妆品有限公司 | 一种深层补水修复面部滋养霜及其制备方法 |
CN112263497A (zh) * | 2020-10-23 | 2021-01-26 | 上海新高姿化妆品有限公司 | 一种具有舒缓修复抗敏功效的护肤品组合物 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114569479A (zh) * | 2021-12-01 | 2022-06-03 | 凡可化妆品研究开发(广州)有限公司 | 一种含泛醇组合物以及护肤品 |
CN114480531A (zh) * | 2021-12-17 | 2022-05-13 | 广州栋方生物科技股份有限公司 | 一种甘油葡糖苷的制备方法、产物及其应用 |
CN114480531B (zh) * | 2021-12-17 | 2024-02-09 | 广州栋方生物科技股份有限公司 | 一种甘油葡糖苷的制备方法、产物及其应用 |
CN115444772A (zh) * | 2022-10-26 | 2022-12-09 | 广州艾卓生物科技股份有限公司 | 一种保湿美白组合物及其在射频美容和医美护肤中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106109296B (zh) | 一种保湿精华水及其制备方法 | |
CN112842985A (zh) | 一种保湿修护组合物 | |
CN110051587A (zh) | 一种含多种玻尿酸的抗衰老组合物的制备方法和应用 | |
WO2021003962A1 (zh) | 一种修复肌肤用护肤组合物及其制备方法 | |
CN108143702A (zh) | 一种高效美白补水面膜液、面膜及其制备方法 | |
JP2001522791A (ja) | 表皮細胞の機能性向上のためのd−キシロース、そのエステル類及びキシロース含有オリゴ糖類の使用。 | |
CN110664644B (zh) | 一种含叶酸的护肤组合物、精华及其制备方法 | |
CN110897901A (zh) | 具有多重补水保湿功效的护肤面膜液及其制备方法 | |
CN112137951A (zh) | 一种强韧发丝修复头皮屏障的无硅油透明氨基酸洗发水及其制备方法 | |
CN110946784A (zh) | 一种具有提升皮肤屏障功能、加强皮肤健康的护肤组合物 | |
CN108451893B (zh) | 一种具有长效保湿功效的化妆水及其制备方法 | |
CN115517999B (zh) | 一种抗衰老组合物及其在美容护肤中的应用 | |
CN111840176A (zh) | 一种具有抗糖基化、美白、祛斑、祛皱作用的美容组合物及其应用 | |
CN115400034A (zh) | 一种保湿修复精华乳及其制备方法 | |
CN108451892B (zh) | 一种具有长效保湿功效的精华液及其制备方法 | |
CN112773761B (zh) | 一种化妆品组合物、精华液及其制备方法 | |
CN107648066A (zh) | 一种含生长因子的抗衰老活肤护肤液及其制备方法 | |
CN107854358A (zh) | 一种抗衰老组合物及含有该组合物的护肤品 | |
CN111012699A (zh) | 一种含褐藻糖海带提取物的抗氧化控油乳液 | |
CN114306125B (zh) | 一种含不同分子量裂褶多糖的组合物及其制备方法和应用 | |
KR20140145274A (ko) | 피부 보습기능을 갖는 산소수 함유 고분자 조성물을 함유하는 화장료 조성물 | |
CN109453104B (zh) | 淡斑爽肤精华液及其制备工艺 | |
CN108852977B (zh) | 一种晶润精华液 | |
CN113384483A (zh) | 提高皮肤弹性,延缓衰老的组合物及其制备方法 | |
CN111973471A (zh) | 化妆品组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210528 |